![David Schilansky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Schilansky
Finanzdirektor/CFO bei
SCANCELL HOLDINGS PLC
Profil
David S.
Schilansky is the founder of Home Biosciences SAS, founded in 2019, where the title held is Chairman & Chief Executive Officer.
Mr. Schilansky is also the founder of One Biosciences SAS. Mr. Schilansky is Chief Financial Officer at Scancell Holdings Plc since 2026.
Former positions include Chief Executive Officer at Ariceum Therapeutics GmbH from 2025 to 2026; Director-Investor Relations at Ipsen International GmbH; Independent Non-Executive Director at Lysogene SA from 2016 to 2022; Head-Investor Relations at Tercica, Inc.; Group Chief Financial Officer at Ipsen SA from 2009 to 2011; Head-Investor Relations at Vantiva Usa Shared Services, Inc. from 2003 to 2006; CFO & Principal Financial & Accounting Officer at DBV Technologies SA from 2014 to 2015; Chief Financial Officer at Ipsen Pharma SAS. Education includes graduate degrees from Imperial College London and Université Paris Dauphine-PSL.
Aktive Positionen von David Schilansky
| Unternehmen | Position | Beginn |
|---|---|---|
| SCANCELL HOLDINGS PLC | Finanzdirektor/CFO | 24.04.2026 |
One Biosciences SAS
 One Biosciences SAS BiotechnologyHealth Technology Provides single-cell technology research and development services | Gründer | 01.07.2020 |
Home Biosciences SAS
 Home Biosciences SAS BiotechnologyHealth Technology Operates as biotechnology company | Vorstandsvorsitzender | 01.01.2019 |
Ehemalige bekannte Positionen von David Schilansky
| Unternehmen | Position | Ende |
|---|---|---|
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Vorstandsvorsitzender | 01.01.2026 |
| LYSOGENE | Direktor/Vorstandsmitglied | 24.06.2022 |
| DBV TECHNOLOGIES | Finanzdirektor/CFO | - |
| IPSEN | Finanzdirektor/CFO | 01.12.2011 |
Vantiva Usa Shared Services, Inc.
 Vantiva Usa Shared Services, Inc. Electronics/AppliancesConsumer Durables Manufactures electronic appliances and products | Investor Relations Kontakt | - |
Ausbildung von David Schilansky
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
46
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology Develops new therapeutics for endocrine system disorders | Health Technology |
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen International GmbH
 Ipsen International GmbH Industrial MachineryProducer Manufacturing Manufactures and distributes furnaces and plant systems | Producer Manufacturing |
Vantiva Usa Shared Services, Inc.
Vantiva Usa Shared Services, Inc. Electronics/AppliancesConsumer Durables Manufactures electronic appliances and products | Consumer Durables |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Université Paris Dauphine-PSL
 Université Paris Dauphine-PSL Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scancell Holdings Plc
 Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Lysogene SA
 Lysogene SA BiotechnologyHealth Technology Engages in research and clinical development of gene therapy for neurodegenerative disorders | Health Technology |
One Biosciences SAS
One Biosciences SAS BiotechnologyHealth Technology Provides single-cell technology research and development services | Health Technology |
Home Biosciences SAS
Home Biosciences SAS BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Health Technology |
Wählen Sie MarketScreener 
